대한메디칼

비상장계속사업자

DaehanMedical co.,Ltd

박종민

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

대한메디칼

Business Reg. No. 2048634445 · CEO 박종민

I.Investment Overview

Target대한메디칼 (2048634445)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명대한메디칼
영문명DaehanMedical co.,Ltd
대표자박종민
사업자등록번호2048634445
법인등록번호1101114866286
설립일2012.05.21
종업원수16명

V.Workforce

16

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW120.52021140.12022142.32023139.62024152.72025
영업이익100M KRW4.120213.9202211.6202313.7202419.72025
순이익100M KRW6.720211.8202210.6202311.4202416.72025
Item20252024202320222021
자산총계174.2억원174.4억원152.6억원148.3억원152.4억원
부채총계110.7억원127.7억원117.3억원123.6억원129.5억원
자본총계63.4억원46.7억원35.3억원24.7억원22.9억원
매출액152.7억원139.6억원142.3억원140.1억원120.5억원
영업이익19.7억원13.7억원11.6억원3.9억원4.1억원
순이익16.7억원11.4억원10.6억원1.8억원6.7억원

VII.Financial Ratios

FY2025 basis

12.89%

영업이익률

10.96%

순이익률

9.61%

ROA

26.39%

ROE

174.55%

부채비율

36.42%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

대한메디칼 투심보고서 | Alpha Lenz